Opinions expressed by Forbes Contributors are their own. Dr. Omer Awan is a practicing physician who covers public health. CARLSBAD, CA-NOV 30TH: Mounjaro injection pen on display at Rachel Graham ...

Eli Lilly said its highly popular weight loss drug Zepbound showed the potential to treat patients with the most common sleep ...

The Food and Drug Administration on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and obesity. Zepbound is the first medication approved ...

Joshua Cohen is a Boston-based writer who covers health policy. Patients on the weight-loss drug Zepbound regained weight almost one year after stopping treatment, according to a study published ...

Zepbound is an injectable prescription medication ... The medication also promotes weight loss, with patients losing an average of 45 pounds or 18% of their body weight, during the trials.

The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder. The weekly injection is now ...

A study suggests that weight loss medications like Ozempic may help ... Eli Lilly says a new trial showed the key ingredient in its popular drugs Zepbound and Mounjaro helped slash the chance ...

The U.S. Food and Drug Administration (FDA ... to managing OSA symptoms while also promoting significant weight loss. Zepbound is an injectable prescription medication created to help adults ...